Across TCGA pan-cancer cohorts, C16orf71 mass-spec protein is linked to patient survival in 1 of 34 cancer types, making it a survival-associated C16orf71 data layer compared with 24 for mass-spec protein and 4 for mutation status.
The strongest signal is observed in lung adenocarcinoma (LUAD), where higher C16orf71 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated C16orf71 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.
LUAD are the cancer types where C16orf71 mass-spec protein most reproducibly stratifies survival.